Abstract

Chronic gastrointestinal (GI) diseases are the most common diseases in captive common marmosets. To understand the role of the microbiome in GI diseases, we characterized the gut microbiome of 91 healthy marmosets (303 samples) and 59 marmosets diagnosed with inflammatory bowel disease (IBD) (200 samples). Healthy marmosets exhibited “humanized,” Bacteroidetes-dominant microbiomes. After up to 2 years of standardized diet, housing and husbandry, marmoset microbiomes could be classified into four distinct marmoset sources based on Prevotella and Bacteroides levels. Using a random forest (RF) model, marmosets were classified by source with an accuracy of 93% with 100% sensitivity and 95% specificity using abundance data from 4 Prevotellaceae amplicon sequence variants (ASVs), as well as single ASVs from Coprobacter, Parabacteroides, Paraprevotella, Phascolarctobacterium, Oribacterium and Fusobacterium. A single dysbiotic IBD state was not found across all marmoset sources, but IBD was associated with lower alpha diversity and a lower Bacteroides:Prevotella copri ratio within each source. IBD was highest in a Prevotella-dominant cohort, and consistent with Prevotella-linked diseases, pro-inflammatory genes in the jejunum were upregulated. RF analysis of serum biomarkers identified serum calcium, hemoglobin and red blood cell (RBC) counts as potential biomarkers for marmoset IBD. This study characterizes the microbiome of healthy captive common marmosets and demonstrates that source-specific microbiomes can be retained despite standardized diets and husbandry practices. Marmosets with IBD had decreased alpha diversity and a shift in the ratio of Bacteroides:Prevotella copri compared to healthy marmosets.

Details

Title
Analysis of gut microbiome profiles in common marmosets (Callithrix jacchus) in health and intestinal disease
Author
Sheh Alexander 1 ; Artim, Stephen C 2 ; Burns, Monika A 1 ; Molina-Mora, Jose Arturo 3 ; Lee, Mary Anne 4 ; Dzink-Fox JoAnn 1 ; Sureshkumar, Muthupalani 1 ; Fox, James G 1 

 Massachusetts Institute of Technology, Division of Comparative Medicine, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, Division of Comparative Medicine, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Merck, Merck Research Laboratories, South San Francisco, USA (GRID:grid.417993.1) (ISNI:0000 0001 2260 0793) 
 Universidad de Costa Rica, Centro de Investigación en Enfermedades Tropicales (CIET), San José, Costa Rica (GRID:grid.412889.e) (ISNI:0000 0004 1937 0706) 
 Massachusetts Institute of Technology, Division of Comparative Medicine, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Wellesley College, Department of Biological Sciences, Wellesley, USA (GRID:grid.268091.4) (ISNI:0000 0004 1936 9561) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2639133217
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.